Article

FDA Briefs - March 1, 2002

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Related Content
Study shows ceftriaxone found effective in treating congenital syphilis
June 11th 2025

Study shows ceftriaxone found effective in treating congenital syphilis

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801
June 5th 2025

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

Swept-source AS-OCT aids in early diagnosis of childhood glaucoma
May 29th 2025

Swept-source AS-OCT aids in early diagnosis of childhood glaucoma

Ocugen’s OCU410ST receives rare pediatric disease designation for the treatment of ABCA4-associated retinopathies
May 27th 2025

Ocugen’s OCU410ST receives rare pediatric disease designation for the treatment of ABCA4-associated retinopathies

© 2025 MJH Life Sciences

All rights reserved.